{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:48:38Z","timestamp":1781560118808,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ijcard.2018.04.122","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T07:34:18Z","timestamp":1524728058000},"page":"183-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective"],"prefix":"10.1016","volume":"267","author":[{"given":"Radya","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tonkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Zomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9753","key":"10.1016\/j.ijcard.2018.04.122_bb0005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ijcard.2018.04.122_bb0010","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.2016.15450","article-title":"Statin use for the primary prevention of cardiovascular disease in adults","volume":"316","author":"US Preventive Services Task Force","year":"2016","journal-title":"J. Am. Med. Assoc."},{"issue":"2","key":"10.1016\/j.ijcard.2018.04.122_bb0015","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinthera.2009.02.017","article-title":"The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis","volume":"31","author":"Delahoy","year":"2009","journal-title":"Clin. Ther."},{"issue":"13","key":"10.1016\/j.ijcard.2018.04.122_bb0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/CIRCULATIONAHA.114.013189","article-title":"Statin intolerance","volume":"131","author":"Fitchett","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijcard.2018.04.122_bb0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2018.04.122_bb0030","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.04.122_bb0035","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/1471-2458-12-398","article-title":"Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study","volume":"12","author":"Cobiac","year":"2012","journal-title":"BMC Public Health"},{"issue":"4","key":"10.1016\/j.ijcard.2018.04.122_bb0040","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCOUTCOMES.111.964700","article-title":"Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010","volume":"5","author":"Smolina","year":"2012","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"issue":"8","key":"10.1016\/j.ijcard.2018.04.122_bb0045","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1161\/01.STR.0000082382.42061.EE","article-title":"Ten-year survival after first-ever stroke in the Perth Community Stroke Study","volume":"34","author":"Hardie","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.04.122_bb0050","author":"National GRIM Books"},{"key":"10.1016\/j.ijcard.2018.04.122_bb0055","author":"National hospital cost data collection"},{"key":"10.1016\/j.ijcard.2018.04.122_bb0060","author":"The Pharmaceutical Benefits Scheme"},{"key":"10.1016\/j.ijcard.2018.04.122_bb0065","author":"Health Expenditure Australia 2013\u201314"},{"key":"10.1016\/j.ijcard.2018.04.122_bb0070","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1524-4733.2004.74002.x","article-title":"Discounting health outcomes in economic evaluation: the ongoing debate","volume":"7","author":"Severens","year":"2004","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.ijcard.2018.04.122_bb0075","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.04.122_bb0080","series-title":"The ODYSSEY OUTCOMES trial: topline results. Alirocumab in patients after acute coronary syndrome. Presented at the American College of Cardiology Scientific Sessions, Orlando Florida; March 10\u201312","author":"Schwartz","year":"2018"},{"issue":"6","key":"10.1016\/j.ijcard.2018.04.122_bb0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/clc.22535","article-title":"Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States","volume":"39","author":"Gandra","year":"2016","journal-title":"Clin. Cardiol."},{"issue":"7","key":"10.1016\/j.ijcard.2018.04.122_bb0090","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"J. Am. Med. Assoc."},{"issue":"6","key":"10.1016\/j.ijcard.2018.04.122_bb0095","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ijcard.2018.04.122_bb0100","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","article-title":"An international model to predict recurrent cardiovascular disease","volume":"125","author":"Wilson","year":"2012","journal-title":"Am. J. Med."},{"issue":"11","key":"10.1016\/j.ijcard.2018.04.122_bb0105","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ijcard.2018.04.122_bb0110","author":"National Center for Health Statistics"},{"issue":"8","key":"10.1016\/j.ijcard.2018.04.122_bb0115","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jama.2017.9924","article-title":"Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial","volume":"318","author":"Kazi","year":"2017","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ijcard.2018.04.122_bb0120","article-title":"Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease","author":"Fonarow","year":"2017","journal-title":"J. Am. Assoc. Cardiol."},{"key":"10.1016\/j.ijcard.2018.04.122_bb0125","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/13696998.2017.1284078","article-title":"Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary prevention population in the US paper context","volume":"20","author":"Toth","year":"2017","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.ijcard.2018.04.122_bb0130","author":"NICE draft guidance recommends new drugs for cholesterol disorder"},{"issue":"22","key":"10.1016\/j.ijcard.2018.04.122_bb0135","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy. A quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2018.04.122_bb0140","first-page":"1385","article-title":"Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal potency statin in a randomized clinical trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"J. Am. Med. Assoc. Cardiol."},{"key":"10.1016\/j.ijcard.2018.04.122_bb0145","series-title":"Clinical Benefit of Evolocumab in Patients With a History of MI: An Analysis From FOURIER. Presented at the American Heart Association Scientific Sessions, Anaheim California; November 11\u201315","author":"Sabatine","year":"2017"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317368225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317368225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T11:46:13Z","timestamp":1530099973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527317368225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":29,"alternative-id":["S0167527317368225"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.04.122","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.04.122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}